导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.08% | 2305/4773 |
| 近一周 | -1.77% | 3282/5467 |
| 近一月 | -5.19% | 2222/5421 |
| 近一季 | -6.89% | 2171/5238 |
| 近半年 | -0.32% | 1675/4931 |
| 近一年 | 2.59% | 2033/4400 |
| 近两年 | 44.12% | 1682/2954 |
| 近三年 | 27.69% | 1162/2253 |
| 成立以来 | 68.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.43% 3201/4961 |
12.86% 2104/5312 |
- - |
- - |
| 2025 | 18.48% 2311/4813 |
-1.17% 2599/3635 |
2.01% 1949/4076 |
16.82% 2596/4524 |
0.60% 1904/4813 |
| 2024 | 15.09% 967/3463 |
4.33% 459/2808 |
-1.05% 906/3014 |
13.40% 2173/3129 |
-1.69% 1795/3463 |
| 2023 | -10.65% 1322/2656 |
2.83% 1295/2280 |
-4.54% 1196/2385 |
-3.35% 902/2515 |
-5.82% 1514/2655 |
| 2022 | -19.22% 819/2207 |
-13.41% 754/1919 |
5.57% 870/2016 |
-11.98% 620/2113 |
0.40% 1499/2208 |
| 2021 | -1.90% 824/1822 |
-3.07% 752/1255 |
6.64% 732/1330 |
-5.66% 842/1466 |
0.61% 1088/1822 |
| 2020 | 39.30% 338/1250 |
-6.67% 502/1028 |
13.22% 638/1067 |
14.41% 277/1164 |
15.23% 225/1184 |
| 2019 | 41.31% 234/1092 |
23.84% 539/754 |
2.21% 94/804 |
3.68% 238/850 |
7.68% 409/918 |
| 2018 | -23.59% 290/834 |
- - |
- - |
- - |
-13.40% 532/691 |
| 2017 | 21.68% 162/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.83% 287/605 |
- - |
- - |
- - |
- - |
| 2015 | 1.43% 244/575 |
- - |
- - |
- - |
- - |
| 2014 | 44.24% 111/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.25% 135/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.54% 52/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.74% 65/102 |
- - |
- - |
- - |
- - |
| 2010 | -11.85% 29/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 银华沪深300指数(LOF) VS. 长安沪深300非周期A(740101) |